
MoonLake Immunotherapeutics (MLTX) Stock Forecast & Price Target
MoonLake Immunotherapeutics (MLTX) Analyst Ratings
Bulls say
MoonLake Immunotherapeutics is positioned favorably due to its focus on SLK, a tri-specific IL-17A and IL-17F inhibiting Nanobody, which has demonstrated robust efficacy in clinical trials and shows potential for disease modification in inflammatory skin and joint disorders. The company is anticipating pivotal data this year, indicating a significant opportunity for growth, particularly in hidradenitis suppurativa (HS), a condition with considerable unmet medical needs and increasing market awareness. Additionally, with sales of comparable therapies like Cosentyx exceeding $970 million, SLK's positive clinical outcomes and potential expansion into other inflammatory indications further support a compelling investment thesis.
Bears say
MoonLake Immunotherapeutics faces significant risks that could lead to a negative outlook on its stock, primarily due to potential safety concerns and efficacy issues related to its drug SLK, which could hinder the progression of clinical trials and the probability of success. The company's recent net loss of $44.2 million in Q4 2024 underscores its financial challenges, while regulatory hurdles and the need for further safety data could introduce delays that affect revenue generation prospects. Furthermore, competitive disadvantages, such as lack of differentiation from existing treatments and the risks associated with being a second-to-market option, create additional uncertainty around the company's future performance.
This aggregate rating is based on analysts' research of MoonLake Immunotherapeutics and is not a guaranteed prediction by Public.com or investment advice.
MoonLake Immunotherapeutics (MLTX) Analyst Forecast & Price Prediction
Start investing in MoonLake Immunotherapeutics (MLTX)
Order type
Buy in
Order amount
Est. shares
0 shares